Treatment
7Chronic inflammatory demyelinating polyneuropathy therapy reference (2026)
Reference snapshot of CIDP therapy across induction, maintenance, and emerging biologic tiers.
Spasticity therapy reference (2026)
Reference snapshot of spasticity therapy across post-stroke, multiple sclerosis, cerebral palsy, and spinal cord injury populations.
Acute ischemic stroke therapy reference (2026)
Reference snapshot of acute ischemic stroke therapy across thrombolysis and mechanical thrombectomy.
Migraine prevention therapy class reference (2026)
Reference snapshot of approved migraine prevention options including CGRP class, traditional preventives, and emerging mechanisms.
Anti-amyloid antibody landscape, 2026 mid-year reference
A dated reference snapshot of the anti-amyloid antibody class for Alzheimer's disease as of mid-2026: approved products, withdrawn products, late-stage pipeline, label-defining clinical evidence, and the operational pattern that defines the class.
DMD treatment landscape, 2026 mid-year reference
Reference layout of the Duchenne muscular dystrophy treatment landscape as of mid-2026: approved mechanisms across exon-skipping, gene therapy, and corticosteroid-class agents, late-stage pipeline, and the live commercial questions across patient populations.
Disease-modifying therapies in Alzheimer's, as of Q2 2026
Two anti-amyloid antibodies have traditional FDA approval; subcutaneous formulations are advancing; the post-amyloid pipeline is portfolio-shaped.
Diagnosis
2Dementia subtype therapy reference (2026)
Reference snapshot of dementia therapy across Alzheimer's, dementia with Lewy bodies, vascular, and frontotemporal subtypes.
Alzheimer's diagnostic pathways, as of Q2 2026
Plasma biomarkers are entering routine workflows alongside established CSF and PET options, with confirmatory imaging still standard before disease-modifying therapy.
Regulatory
1Access
2Caregiver support landscape for Alzheimer's disease, as of Q2 2026
A reference view of the federal, state, employer, and direct-support programs that currently exist for unpaid family caregivers of people with Alzheimer's disease in the US, with notes on the UK and EU.
Payer coverage for anti-amyloid therapy, as of Q2 2026
A reference view of how anti-amyloid therapy is currently covered across US Medicare, Medicare Advantage, US commercial payers, and select international markets.
Pipeline
1Drug development
2What we are watching in Alzheimer's, as of Q2 2026
A reference list of the threads PatientSpotlight is actively tracking - clinical readouts, regulatory and reimbursement decisions, real-world evidence accumulation, and operational rollout. Each thread names what to watch and why it matters, without predicting when it will resolve.
Clinical trial endpoints in Alzheimer's disease, as of Q2 2026
A reference view of the cognitive, functional, and biomarker endpoints used in late-stage Alzheimer's trials - what each measures and how to read a readout that uses it.